

PHARMACEUTICAL 2023

Ayala Pharmaceuticals Inc. Rank 110 of 446









PHARMACEUTICAL 2023



## RealRate

Ayala Pharmaceuticals Inc. Rank 110 of 446

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Ayala Pharmaceuticals Inc. is the variable Expenses, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 143% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	25,759
Cost of Goods Sold	0
Intangible Assets	110
Liabilities, Current	2,303
Liabilities, Non-Current	0
Other Assets	23
Other Compr. Net Income	0
Other Expenses	3,103
Other Liabilities	0
Other Net Income	5,001
Other Revenues	250
Property and Equipment	38
Research and Development	7,616
Selling, General and Administrative Expense	8,891

Output Variable	Value in 1000 USD
Assets	25,930
Liabilities	2,303
Expenses	19,610
Revenues	250
Stockholders Equity	23,627
Net Income	-14,359
Comprehensive Net Income	-14,359
Economic Capital Ratio	186%

